The overall objecfive of this project is to utilize genomic and genetic data obtained from human pancreatic cancer (PCa) samples and observations from mouse models of PCa to understand the genetic events that drive tumor progression and treatment resistance in this disease. These mouse models include recent observations about PCa genesis and novel Sleeping Beauty (SB) transposon-based, forward genefic screens for PCa. The human PCa samples have been obtained from a novel collection via a rapid autopsy program developed by co-leader Christine lacobuzio-Donahue and fine needle aspirations (FNA) obtained by members of this SPORE group. These samples are being profiled for genetic alterations and markers identified in the mouse models. This has provided insight into the genetic drivers of PCa development and candidates for causing speciflc PCa phenotypes such as metastatic spread. We will discover novel genefic correlates of tumor progression, metastasis, and outcome using gene copy number, mRNA levels, sequence alterations and immunohistochemistry. Functional validation of novel targets will take place using gene overexpression or shRNA gene """"""""knockdown"""""""" in PCa cell lines, xenografts, and mouse transgenic models. Moreover, these mulfi-dimensional data will be the basis for investigafing pharmacological suppression of pathways that cooperate to drive PCa development and progression. Our inifial focus is on a novel regulator of the TGF-beta and other pathways called Usp9x, and PTEN-regulated pathways. These experiments will set the stage for new clinical trials for PCa to be carried out during the next project period.
Pancreatic cancer remains a massive clinical challenge because key steps in the progression of the disease are still not idenfified. Also, the specific cooperating mutations and pathways that combine to make this cancer deadly are not identifled. This proposal will idenfify these cooperafing pathways and test therapies based on this knowledge.
|Roe, Jae-Seok; Hwang, Chang-Il; Somerville, Tim D D et al. (2017) Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170:875-888.e20|
|Feigin, Michael E; Garvin, Tyler; Bailey, Peter et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet 49:825-833|
|Chio, Iok In Christine; Tuveson, David A (2017) ROS in Cancer: The Burning Question. Trends Mol Med 23:411-429|
|Öhlund, Daniel; Handly-Santana, Abram; Biffi, Giulia et al. (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214:579-596|
|Zhong, Yi; Macgregor-Das, Anne; Saunders, Tyler et al. (2017) Mutant p53 Together with TGF? Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 23:1607-1620|
|Contreras, Carlo M; Lin, Chee Paul; Oster, Robert A et al. (2017) Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base. Am J Surg 214:442-449|
|Kim, Harrison; Buchsbaum, Donald J; Zinn, Kurt R (2016) A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models. Mol Imaging Biol 18:325-33|
|Reddy, Sushanth; Contreras, Carlo M; Singletary, Brandon et al. (2016) Timed Stair Climbing Is the Single Strongest Predictor of Perioperative Complications in Patients Undergoing Abdominal Surgery. J Am Coll Surg 222:559-66|
|Ho, Yen-Yi; Guan, Weihua; O'Connell, Michael et al. (2016) Powerful association test combining rare variant and gene expression using family data from Genetic Analysis Workshop 19. BMC Proc 10:251-255|
|Malfatti, Michael A; Kuhn, Edward A; Turteltaub, Kenneth W et al. (2016) Disposition of the Dietary Mutagen 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline in Healthy and Pancreatic Cancer Compromised Humans. Chem Res Toxicol 29:352-8|
Showing the most recent 10 out of 166 publications